Tag: EXCESSIVE DAYTIME SLEEPINESS

Marry Murray Patient Voices Column with Project Sleep
Idiopathic Hypersomnia Patient Advocacy

Nap Roulette

My family loves to play games. One of the first things my husband and I bonded over was board games, and we passed that love of games to our children. As a family, we enjoy playing board games like Settlers of Catan and Carcassonne and card games like Dominion and […]

Jazz Pharmaceuticals AAN, Phase 4 DUET trial, Xywav, Epidiolex
Sleep Pharmaceuticals

Jazz Pharmaceuticals to Showcase Research Demonstrating Treatment Benefits of Xywav at AAN

Jazz Pharmaceuticals plc announced that seven abstracts from across its neuroscience portfolio will be featured at the 77th Annual American Academy of Neurology Meeting (AAN) being held 四月 5-9, 2025, in San Diego. Data presented at the meeting includes an updated presentation of top-line results of the open-label, single-arm, Phase 4 DUET (Develop hypersomnia Understanding by Evaluating […]

WAKIX Revenue to Exceed $1B in 2026
Sleep Pharmaceuticals

Promising Results for Pitolisant in Prader-Willi Syndrome

Harmony Biosciences Holdings, Inc. announced the presentation of new secondary endpoint data, including improvements in behavioral disturbances, from its Phase 2 signal-detection study evaluating pitolisant for the treatment of excessive daytime sleepiness (EDS) in Prader-Willi syndrome (PWS) at the 2023 Foundation for Prader-Willi Research (FPWR) Symposium and Family Conference. The […]

excessive sleepiness
病患健康與照護

New Clinical Guideline Recommendations for Sleep Disorders that Cause Excessive Sleepiness

A new clinical practice guideline developed by the American Academy of Sleep Medicine provides recommendations for the treatment of central disorders of hypersomnolence. These sleep disorders cause excessive sleepiness despite a sufficient amount of nocturnal sleep. The guideline, available online as an accepted paper in the Journal of Clinical Sleep Medicine, […]

xywave jazz narcolepsy cataplexy eds
Sleep Pharmaceuticals Idiopathic Hypersomnia

Jazz Presents Phase 3 Results of Xywav in Adults with Idiopathic Hypersomnia

Jazz Pharmaceuticals plc has announced positive results from the Phase 3 study of XywavTM (calcium, magnesium, potassium, and sodium oxybates) oral solution in adult patients with idiopathic hypersomnia, which will be presented during the Clinical Trials Plenary Session of the 2021 American Academy of Neurology (AAN) Annual Meeting. The presentation will further […]